Peter Shapoval, | |
4545 Se Ina Ave Apt 9, Milwaukie, OR 97267-5918 | |
(503) 654-5678 | |
(503) 654-1236 |
Full Name | Peter Shapoval |
---|---|
Gender | Male |
Speciality | Social Worker - Clinical |
Location | 4545 Se Ina Ave Apt 9, Milwaukie, Oregon |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1093111437 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Peter Shapoval, 3587 Heathrow Way, Medford, OR 97504-4004 Ph: (541) 858-8170 | Peter Shapoval, 4545 Se Ina Ave Apt 9, Milwaukie, OR 97267-5918 Ph: (503) 654-5678 |
News Archive
From birthday cakes to Thanksgiving pie to cold summer treats, every holiday, season or special occasion harkens mouth-watering memories of a favorite sugary treat.
The U.S. Food and Drug Administration today allowed marketing of the Xpert MTB/RIF Assay, the first FDA-reviewed test that can simultaneously detect bacteria that cause tuberculosis and determine if the bacteria contain genetic markers that makes them resistant to rifampin, an important antibiotic for the treatment of TB.
A group of Ohio AIDS advocates, patients and medical providers hosted a protest in Columbus today in conjunction with a public hearing held by the Ohio Department of Health (ODH) and its Director, Theodore E. Wymyslo, M.D., on proposed rule changes that would restrict access to lifesaving AIDS drugs for low-income Ohioans based on medical criteria.
Mylan Inc. (Nasdaq: MYL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Mylan Pharmaceutical Inc.'s abbreviated new drug application (ANDA) for Glatiramer Acetate Injection (20 mg/mL), a generic version of Teva's Copaxone(R), a product indicated for the treatment of multiple sclerosis.
Astellas Pharma US, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis.
› Verified 6 days ago
Suzanne Lapidus, Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 6605 Se Lake Rd, Milwaukie, OR 97222 Phone: 503-655-8401 Fax: 503-655-8429 | |
Rachel Diane Keast, CSWA Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2403 Se Monroe St Ste A, Milwaukie, OR 97222 Phone: 515-209-9386 | |
Yvonne Marie Smith, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 12530 Se Shell Ln, Milwaukie, OR 97222 Phone: 503-957-4249 | |
Mr. Justin David Galasso, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 10202 Se 32nd Ave, Milwaukie, OR 97222 Phone: 503-496-1190 | |
Mr. Craig Andrew Nielsen, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 17070 Se Mcloughlin Blvd, Milwaukie, OR 97267 Phone: 503-303-4000 | |
Mary Cosentino-cathey, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 11376 Se Linwood Ave, Milwaukie, OR 97222 Phone: 971-533-0497 |